Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Opus Genetics Inc
IRD
Healthcare
Opus Genetics, Inc., formerly Ocuphire Pharma, Inc., is a clinical-stage ophthalmic biopharmaceutical company. The Company is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes...
that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:IRD)
New Post
View:
Posts & Comments
Threaded Posts
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 12, 2024 10:32pm
Opus Genetics Announces Financial Results for Third Quarter
JUST IN: $IRD Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateIn October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage
...more
(57)
•••
joebravo
X
View Profile
View Bullboard History
Comment by
joebravo
on Sep 27, 2023 8:25am
RE:FDA PDUFA Date September 28, 2023
And there you have it. FDA Approval of Nyxol RM, which will be manufactured and sold under the name RYZUMVI by Viatris starting first half of 2024. Ocuphire will now receive their first
...more
GameSquare Holdings Reports Record 2024 Third Quarter Results
posted Nov 15, 2024 9:00am by
GameSquare Holdings Inc.
-
|
Justin Kenna, CEO of GameSquare, stated, "GameSquare delivered strong third quarter financial results that were in line with our pre-announcement, and reflect the strategies underway to drive organic sales growth, complete the integration of our recent acquisitions, and build a profitable organization. On a sequential basis, I am encouraged by the ...read more
(57)
•••
joebravo
X
View Profile
View Bullboard History
Post by
joebravo
on Sep 13, 2023 8:57am
FDA PDUFA Date September 28, 2023
Not sure why this board has very little following, but this little company with a small float of 21 million shares is about to receive a FDA decision in 2 weeks which could potentially double their
...more
(67)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 24, 2021 10:42am
OCUP....early a.m runner up on NR
You better be looking both ways on this ...... THere is a Shelf Offering on the table This will come back to bite you real hard JMHO
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?